Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages

  Tamiya, Akihiro ^a   Okamoto, Isamu ^b   Miyazaki, Masaki ^b   Shimizu, Shigeki ^a   Kitaichi, Masanori ^a   Nakagawa, Kazuhiko ^b  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIPROFLOXACIN; COTRIMOXAZOLE; CRIZOTINIB; ECHINODERM MICROTUBULE ASSOCIATED LIKE PROTEIN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; MEROPENEM; METHYLPREDNISOLONE; PACLITAXEL; PROTEIN; PROTEIN ALK; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; DYSPNEA; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; MALE; PLEURA METASTASIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; WILD TYPE;

ACUTE DISEASE; ADENOCARCINOMA; ADULT; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; GENE REARRANGEMENT; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84871792236     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3730     Document Type: Article

References (12)

1. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
2. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
3. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
4. Kudoh S, Kato H, Nishiwaki Y, et al: Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study. Am J Respir Crit Care Med 177:1348-1357, 2008
5. Cohen MH, Williams GA, Sridhara R, et al: FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306, 2003
6. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination - The Consensus Committee. Intensive Care Med 20:225-232, 1994
7. Okamoto I, Fujii K, Matsumoto M, et al: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40:339-342, 2003
8. Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139, 2003
9. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007
10. Soda M, Takada S, Takeuchi K, et al: A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105:19893-19897, 2008
11. Takezawa K, Okamoto I, Nishio K, et al: Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 17:2140-2148, 2011
12. Ando M, Okamoto I, Yamamoto N, et al: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549-2556, 2006